Navigation

Lilly drug slows Alzheimer's progression by 35% in trial

Lilly drug slows Alzheimer's progression by 35% in trial
An experimental Alzheimer's drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for another treatment for the brain disorder that slowly destroys memory.


Share

Excelsio Media

EXCELSIO Media

Post A Comment:

0 comments:

Leave a comment. Thanks!